Brokers Set Expectations for electroCore FY2025 Earnings

electroCore, Inc. (NASDAQ:ECOR) – Research analysts at Brookline Capital Management issued their FY2025 earnings per share estimates for electroCore in a note issued to investors on Tuesday, February 3rd. Brookline Capital Management analyst F. Ahmed expects that the company will earn ($1.70) per share for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. Brookline Capital Management also issued estimates for electroCore’s Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.33) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.53) EPS.

electroCore (NASDAQ:ECOR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.07). The company had revenue of $8.69 million for the quarter, compared to analyst estimates of $7.84 million. electroCore had a negative return on equity of 447.87% and a negative net margin of 47.46%.

ECOR has been the subject of a number of other reports. Wall Street Zen upgraded shares of electroCore from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research downgraded electroCore from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of electroCore in a report on Monday, December 29th. Finally, HC Wainwright lowered their target price on electroCore from $25.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $22.00.

electroCore Trading Down 8.6%

ECOR stock opened at $5.07 on Friday. The company’s 50-day moving average price is $5.58 and its 200 day moving average price is $5.44. electroCore has a 52 week low of $4.16 and a 52 week high of $19.49. The company has a market cap of $40.56 million, a P/E ratio of -2.96 and a beta of 0.48.

Institutional Trading of electroCore

Institutional investors and hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC boosted its stake in shares of electroCore by 857.9% during the first quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock valued at $1,083,000 after acquiring an additional 145,047 shares during the last quarter. Tejara Capital Ltd purchased a new position in electroCore in the 4th quarter valued at about $450,000. International Assets Investment Management LLC boosted its stake in shares of electroCore by 15.2% during the 4th quarter. International Assets Investment Management LLC now owns 88,720 shares of the company’s stock worth $398,000 after purchasing an additional 11,700 shares during the last quarter. Jaffetilchin Investment Partners LLC grew its holdings in shares of electroCore by 7.4% during the fourth quarter. Jaffetilchin Investment Partners LLC now owns 52,363 shares of the company’s stock worth $235,000 after buying an additional 3,600 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of electroCore by 114.4% during the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock worth $246,000 after buying an additional 19,599 shares in the last quarter. 26.74% of the stock is currently owned by hedge funds and other institutional investors.

electroCore Company Profile

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.